Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

被引：0
|
作者：
Sonia Zaibet
Vincent Hautefeuille
Edouard Auclin
Astrid Lièvre
David Tougeron
Mathieu Sarabi
Marine Gilabert
Julie Wasselin
Julien Edeline
Pascal Artru
Dominique Bechade
Clémence Morin
Agnes Ducoulombier
Julien Taieb
Simon Pernot
机构：
[1] Université de Paris,Department of Hepato
[2] SIRIC CARPEM Comprehensive Cancer Center,Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou
[3] CHU Amiens Picardie,Department of Hepato
[4] Université de Paris,Gastroenterology and Gastrointestinal Oncology
[5] SIRIC CARPEM Comprehensive Cancer Center,Department of Medical Oncology, Hôpital Européen Georges Pompidou
[6] Université de Paris,INSERM, UMR 1138, team 22, Centre de Recherche des Cordeliers
[7] CHU Rennes,Department of Gastroenterology
[8] INSERM U1242,Department of Hepato
[9] CHU Poitiers,Gastroenterology
[10] Centre Léon Bérard,Department of Medical Oncology
[11] Institut Paoli-Calmettes,Department of Medical Oncology
[12] Centre Eugène Marquis,Department of Medical Oncology
[13] Hôpital Privé Jean Mermoz,Department of Hepato
[14] Institut Bergonié,Gastroenterology
[15] Centre Antoine Lacassagne,Department of Medical Oncology
来源：
British Journal of Cancer | 2022年 / 126卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：969 / 969
相关论文
共 50 条
  • [21] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [22] EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE CHEMOTHERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA AFTER GEMCITABINE PLUS NAB-PACLITAXEL FAILURE
    Ikezawa, Kenji
    Kiyota, Ryosuke
    Takada, Ryoji
    Imai, Toshihiro
    Yutaro, Abe
    Fukutake, Nobuyasu
    Takatoshi, Nawa
    Katayama, Kazuhiro
    Ohkawa, Kazuyoshi
    GASTROENTEROLOGY, 2020, 158 (06) : S527 - S527
  • [23] Clinical outcomes of FOLFIRINOX and gemcitabine/nab-paclitaxel in the real world setting
    Franco, Fernando Franco
    Juan, Camara C.
    Valades, Jose Ignacio Martin
    Marrupe, David
    Abad, David Gutierrez
    Leon, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2019, 37 : 797 - 797
  • [25] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [26] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [27] FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis
    Matsumoto, Toshihiko
    Kimura, Shogo
    Himei, Hitomi
    Okazaki, Ukyo
    Kurioka, Yusuke
    Tsuduki, Takao
    Takagi, Shijiro
    Takatani, Masahiro
    Hiramatsu, Ysushi
    Morishita, Hirofumi
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [29] Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis
    El Rassy, Elie
    Assi, Tarek
    El Karak, Fadi
    Ghosn, Marwan
    Kattan, Joseph
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2017, 41 (02) : E26 - E28
  • [30] Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX
    Vreeland, Timothy J.
    McAllister, Florencia
    Javadi, Sanaz
    Prakash, Laura R.
    Fogelman, David R.
    Ho, Linus
    Varadhachary, Gauri
    Aloia, Thomas A.
    Vauthey, Jean-Nicolas
    Lee, Jeffrey E.
    Kim, Michael P.
    Katz, Matthew H. G.
    Tzeng, Ching-Wei D.
    PANCREAS, 2019, 48 (06) : 837 - 843
12345